Kenneth S. Thomson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kenneth S. Thomson has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Gina K. Thomson
University of Louisville Hospital, Louisville, Kentucky, USA
4 shared publicationsSameh AbdelGhani
University of Louisville School of Medicine, Department of Pathology and Laboratory Medicine Louisville, Kentucky, United States of America
4 shared publications- Gina K. Thomson
Department of Pathology and Laboratory Medicine, School of Medicine, University of Louisville, Louisville, Kentucky, USA
2 shared publications James W. Snyder
University of Louisville School of Medicine, Louisville, Kentucky, USA
2 shared publications- Amal Eissa Saafan
Department of Pharmaceutical Microbiology and Immunology, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt
1 shared publication Andrew Deeb
Department of Medical Microbiology and Immunology, Creighton University School of Medicine, Omaha, Nebraska
1 shared publication
Latest Publications
- 1 January 2022
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 102 (1) , 115554
Rapid identification from rectal swabs of the clinically most relevant carbapenemase genes from gram-negative bacteria using the BD MAX Check-Points CPO Assay
- 1 January 2022
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 102 (1) , 115554
Rapid identification from rectal swabs of the clinically most relevant carbapenemase genes from gram-negative bacteria using the BD MAX Check-Points CPO Assay
- 25 April 2021
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 40 (10) , 2105-2112
Digital imaging for reading of direct rapid antibiotic susceptibility tests from positive blood cultures
Delaying effective antibiotic therapy is a major cause of sepsis-associated mortality. The EUCAST rapid antibiotic susceptibility test (RAST) is performed from positive blood cultures to provide rapid results. Disc diffusion tests inoculated with positive blood culture broth are read at 4, 6, and 8 h and interpreted against species and time-specific criteria. Potential problems are the possibility of missing specific reading times for tests and slower growth in incubators that are frequently opened. The current study aimed to assess if digital visualization by the BD Kiestra™ total laboratory automation system is suitable for reading RASTs by capturing images at the correct times and retaining them for review. Utilizing the Kiestra™ InoqulA, 100 μl of positive blood culture broth was lawn-inoculated onto Mueller-Hinton agar and incubated at 35 °C for automated digital zone measurement at 4, 6, and 8 h. Aliquots from 135 positive blood cultures were tested against EUCAST-recommended and other drugs and assessed for readability of digital images. Microdilution MICs were determined in parallel to RASTs. All isolates except 7/10 enterococci yielded images of suitable quality for zone measurement. Of the 641 digitally read tests for other organisms, 207 (32.3%) were readable in 4 h, 555 (86.6%) in 6 h, and 641 (100%) in 8 h. For tests included in EUCAST criteria, 92.1% provided categorical agreement with microdilution MICs. Digital image reading of RASTs is a potentially viable, inexpensive tool for providing rapid susceptibility results which can help reduce sepsis-associated mortality.
- 25 April 2021
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 40 (10) , 2105-2112
Digital imaging for reading of direct rapid antibiotic susceptibility tests from positive blood cultures
Delaying effective antibiotic therapy is a major cause of sepsis-associated mortality. The EUCAST rapid antibiotic susceptibility test (RAST) is performed from positive blood cultures to provide rapid results. Disc diffusion tests inoculated with positive blood culture broth are read at 4, 6, and 8 h and interpreted against species and time-specific criteria. Potential problems are the possibility of missing specific reading times for tests and slower growth in incubators that are frequently opened. The current study aimed to assess if digital visualization by the BD Kiestra™ total laboratory automation system is suitable for reading RASTs by capturing images at the correct times and retaining them for review. Utilizing the Kiestra™ InoqulA, 100 μl of positive blood culture broth was lawn-inoculated onto Mueller-Hinton agar and incubated at 35 °C for automated digital zone measurement at 4, 6, and 8 h. Aliquots from 135 positive blood cultures were tested against EUCAST-recommended and other drugs and assessed for readability of digital images. Microdilution MICs were determined in parallel to RASTs. All isolates except 7/10 enterococci yielded images of suitable quality for zone measurement. Of the 641 digitally read tests for other organisms, 207 (32.3%) were readable in 4 h, 555 (86.6%) in 6 h, and 641 (100%) in 8 h. For tests included in EUCAST criteria, 92.1% provided categorical agreement with microdilution MICs. Digital image reading of RASTs is a potentially viable, inexpensive tool for providing rapid susceptibility results which can help reduce sepsis-associated mortality.
- Open Access
- 11 December 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (12) , e0220586
CPO Complete, a novel test for fast, accurate phenotypic detection and classification of carbapenemases
Carbapenemase-producing organisms (CPOs) are Gram-negative bacteria that are typically resistant to most or all antibiotics and are responsible for a global pandemic of high mortality. Rapid, accurate detection of CPOs and the classification of their carbapenemases are valuable tools for reducing the mortality of the CPO-associated infections, preventing the spread of CPOs, and optimizing use of new β-lactamase inhibitor combinations such as ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam. The current study evaluated the performance of CPO Complete, a novel, manual, phenotypic carbapenemase detection and classification test. The test was evaluated for sensitivity and specificity against 262 CPO isolates of Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii and 67 non-CPO isolates. It was also evaluated for carbapenemase classification accuracy against 205 CPOs that produced a single carbapenemase class. The test exhibited 100% sensitivity 98.5% specificity for carbapenemase detection within 90 minutes and detected 74.1% of carbapenemases within 10 minutes. In the classification evaluation, 99.0% of carbapenemases were correctly classified for isolates that produced a single carbapenemase. The test is technically simple and has potential for adaptation to automated instruments. With lyophilized kit storage at temperatures up to 38°C, the CPO Complete test has the potential to provide rapid, accurate carbapenemase detection and classification in both limited resource and technologically advanced laboratories.
- 11 December 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (12) , e0220586
Open AccessCPO Complete, a novel test for fast, accurate phenotypic detection and classification of carbapenemases
Carbapenemase-producing organisms (CPOs) are Gram-negative bacteria that are typically resistant to most or all antibiotics and are responsible for a global pandemic of high mortality. Rapid, accurate detection of CPOs and the classification of their carbapenemases are valuable tools for reducing the mortality of the CPO-associated infections, preventing the spread of CPOs, and optimizing use of new β-lactamase inhibitor combinations such as ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam. The current study evaluated the performance of CPO Complete, a novel, manual, phenotypic carbapenemase detection and classification test. The test was evaluated for sensitivity and specificity against 262 CPO isolates of Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii and 67 non-CPO isolates. It was also evaluated for carbapenemase classification accuracy against 205 CPOs that produced a single carbapenemase class. The test exhibited 100% sensitivity 98.5% specificity for carbapenemase detection within 90 minutes and detected 74.1% of carbapenemases within 10 minutes. In the classification evaluation, 99.0% of carbapenemases were correctly classified for isolates that produced a single carbapenemase. The test is technically simple and has potential for adaptation to automated instruments. With lyophilized kit storage at temperatures up to 38°C, the CPO Complete test has the potential to provide rapid, accurate carbapenemase detection and classification in both limited resource and technologically advanced laboratories.
- Open Access
CPO Complete, a novel test for fast, accurate phenotypic detection and classification of carbapenemases
Rapid, accurate detection of carbapenemase-producing organisms (CPOs) and the classification of their carbapenemases are valuable tools for reducing the mortality of the CPO-associated infections, preventing the spread of CPOs, and optimizing use of new β-lactamase inhibitor combinations such as ceftazidime/avibactam and meropenem/vaborbactam. The current study evaluated the performance of CPO Complete, a novel, manual, phenotypic carbapenemase detection and classification test. The test was evaluated for sensitivity and specificity against 262 CPO isolates of Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii and 67 non-CPO isolates. It was also evaluated for carbapenemase classification accuracy against 205 CPOs that produced a single carbapenemase class. The test exhibited 100% sensitivity 98.5% specificity for carbapenemase detection within 90 minutes and detected 74.1% of carbapenemases within 10 minutes. In the classification evaluation, 99.0% of carbapenemases were correctly classified. The test is technically simple and has potential for adaptation to automated instruments. With lyophilized kit storage at temperatures up to 38°C the CPO Complete test has the potential to provide rapid, accurate carbapenemase detection and classification in both limited resource and technologically advanced laboratories.
Open AccessCPO Complete, a novel test for fast, accurate phenotypic detection and classification of carbapenemases
Rapid, accurate detection of carbapenemase-producing organisms (CPOs) and the classification of their carbapenemases are valuable tools for reducing the mortality of the CPO-associated infections, preventing the spread of CPOs, and optimizing use of new β-lactamase inhibitor combinations such as ceftazidime/avibactam and meropenem/vaborbactam. The current study evaluated the performance of CPO Complete, a novel, manual, phenotypic carbapenemase detection and classification test. The test was evaluated for sensitivity and specificity against 262 CPO isolates of Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii and 67 non-CPO isolates. It was also evaluated for carbapenemase classification accuracy against 205 CPOs that produced a single carbapenemase class. The test exhibited 100% sensitivity 98.5% specificity for carbapenemase detection within 90 minutes and detected 74.1% of carbapenemases within 10 minutes. In the classification evaluation, 99.0% of carbapenemases were correctly classified. The test is technically simple and has potential for adaptation to automated instruments. With lyophilized kit storage at temperatures up to 38°C the CPO Complete test has the potential to provide rapid, accurate carbapenemase detection and classification in both limited resource and technologically advanced laboratories.
- Open Access
- 23 March 2019
- Published by MDPI AG in Antibiotics
- Vol. 8 (1) , 32
Activity of Cefepime-Zidebactam against Multidrug-Resistant (MDR) Gram-Negative Pathogens
This study compared the activity of cefepime + zidebactam (FEP-ZID) and selected currently available antibacterial agents against a panel of multidrug-resistant (MDR) clinical isolates chosen to provide an extreme challenge for antibacterial activity. FEP–ZID had a very broad and potent in vitro spectrum of activity, and was highly active against many MDR isolates of Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii. Notably, it inhibited isolates producing carbapenemases of Ambler classes A, B, and D, and P. aeruginosa isolates with multiple resistance mechanisms including combinations of upregulated efflux, diminished or non-functional OprD porins, and AmpC overproduction. Its clinical role will be determined initially by the breakpoints assigned to it, comparison studies with other investigational β-lactamase inhibitor combinations, and ultimately by the developing body of therapeutic outcome data.
- 23 March 2019
- Published by MDPI AG in Antibiotics
- Vol. 8 (1) , 32
Open AccessActivity of Cefepime-Zidebactam against Multidrug-Resistant (MDR) Gram-Negative Pathogens
This study compared the activity of cefepime + zidebactam (FEP-ZID) and selected currently available antibacterial agents against a panel of multidrug-resistant (MDR) clinical isolates chosen to provide an extreme challenge for antibacterial activity. FEP–ZID had a very broad and potent in vitro spectrum of activity, and was highly active against many MDR isolates of Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii. Notably, it inhibited isolates producing carbapenemases of Ambler classes A, B, and D, and P. aeruginosa isolates with multiple resistance mechanisms including combinations of upregulated efflux, diminished or non-functional OprD porins, and AmpC overproduction. Its clinical role will be determined initially by the breakpoints assigned to it, comparison studies with other investigational β-lactamase inhibitor combinations, and ultimately by the developing body of therapeutic outcome data.
- 1 January 2018
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 56 (1)
An Improved Extended-Spectrum-β-Lactamase Detection Test Utilizing Aztreonam plus Clavulanate
Clinical laboratories test for ESBLs for epidemiological and infection control purposes and also for potential to cause therapeutic failures with cephalosporins. Testing can be problematic because the CLSI does not recommend testing of all producers of ESBLs and also falsely negative results may occur with isolates that co-produce AmpC. Boronic acid supplemented tests can enhance ESBL detection in AmpC producers. Because aztreonam inhibits AmpCs, a study was designed to compare ESBL detection by the CLSI disk test (CLSI), a boronic acid supplemented CLSI disk test (CLSI + BA), and an aztreonam + clavulanate disk test (ATM + CA). The study tested 100 well-characterized Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa. Seventy produced TEM, SHV or CTX-M ESBLs, with 15 co-producing an AmpC, and 11 co-producing a metallo-β-lactamase. Thirty ESBL-negative isolates were also tested. Tests were inoculated by CLSI methodology and interpreted as positive if an inhibitor caused a zone diameter increase of ≥ 5 mm. The percent of ESBL producers detected were ATM + CA, 95.7%; CLSI + BA, 88.6%, and CLSI, 78.6%. When AmpC was co-produced, the sensitivities of the tests were: ATM + CA, 100%; CLSI + BA, 93.3%; and CLSI, 60%. ATM + CA also detected an ESBL in 90.1% of isolates that co-produced a metallo-β-lactamase. Falsely positive tests occurred only with the CLSI and CLSI + BA tests. Overall, the ATM + CA test detected ESBLs more accurately than the CLSI and CLSI + BA tests, especially with isolates co-producing an AmpC or metallo-β-lactamase.
- 1 January 2018
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 56 (1)
An Improved Extended-Spectrum-β-Lactamase Detection Test Utilizing Aztreonam plus Clavulanate
Clinical laboratories test for ESBLs for epidemiological and infection control purposes and also for potential to cause therapeutic failures with cephalosporins. Testing can be problematic because the CLSI does not recommend testing of all producers of ESBLs and also falsely negative results may occur with isolates that co-produce AmpC. Boronic acid supplemented tests can enhance ESBL detection in AmpC producers. Because aztreonam inhibits AmpCs, a study was designed to compare ESBL detection by the CLSI disk test (CLSI), a boronic acid supplemented CLSI disk test (CLSI + BA), and an aztreonam + clavulanate disk test (ATM + CA). The study tested 100 well-characterized Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa. Seventy produced TEM, SHV or CTX-M ESBLs, with 15 co-producing an AmpC, and 11 co-producing a metallo-β-lactamase. Thirty ESBL-negative isolates were also tested. Tests were inoculated by CLSI methodology and interpreted as positive if an inhibitor caused a zone diameter increase of ≥ 5 mm. The percent of ESBL producers detected were ATM + CA, 95.7%; CLSI + BA, 88.6%, and CLSI, 78.6%. When AmpC was co-produced, the sensitivities of the tests were: ATM + CA, 100%; CLSI + BA, 93.3%; and CLSI, 60%. ATM + CA also detected an ESBL in 90.1% of isolates that co-produced a metallo-β-lactamase. Falsely positive tests occurred only with the CLSI and CLSI + BA tests. Overall, the ATM + CA test detected ESBLs more accurately than the CLSI and CLSI + BA tests, especially with isolates co-producing an AmpC or metallo-β-lactamase.
- Open Access
- 1 December 2017
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 55 (12) , 3437-3443
High-Stringency Evaluation of the Automated BD Phoenix CPO Detect and Rapidec Carba NP Tests for Detection and Classification of Carbapenemases
There is an urgent need for rapid, accurate detection and classification of carbapenemases. The current study evaluated the automated BD Phoenix CPO Detect and the manual bioMérieux Rapidec Carba NP tests for meeting these needs. Both tests were challenged with 294 isolates of Enterobacteriaceae spp., Pseudomonas aeruginosa , and Acinetobacter baumannii chosen to provide extreme diagnostic difficulty. Carbapenemases such as KPC, NMC-A, IMI, SME, NDM, SPM, IMP, VIM, and OXA-23, 40, 48, 58, 72, 181, and 232 were produced by 243 isolates and 51 carbapenemase-negative isolates included porin mutants and producers of extended-spectrum β-lactamases (ESBLs), AmpCs, K1, and broad-spectrum β-lactamases. Both tests exhibited high sensitivity of carbapenemase detection (>97%). Due to the highly challenging carbapenemase-negative isolates, specificities were lower than typical for evaluations involving mostly routine clinical isolates. BD Phoenix CPO Detect was 68.6% specific and Rapidec Carba NP was 60.8% to 78.4% specific, depending on how borderline results were interpreted. Only BD Phoenix CPO Detect classified carbapenemases. It correctly classified 85.0% of class A, 72.4% of class B, and 88.6% of class D carbapenemases. Importantly with respect to empirical therapy with new β-lactamase inhibitor combinations such as ceftazidime/avibactam, no class B carbapenemases were misclassified as class A carbapenemases. Both tests offer advantages. Used alone, without initial susceptibility tests, Rapidec Carba NP can provide positive results for some isolates after only 10 to 30 min incubation. BD Phoenix CPO Detect provides novel advantages such as automated carbapenemase detection, inclusion in susceptibility panels to eliminate delays and subjectivity in initiating carbapenemase tests, and classification of most carbapenemases.
- 1 December 2017
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 55 (12) , 3437-3443
Open AccessHigh-Stringency Evaluation of the Automated BD Phoenix CPO Detect and Rapidec Carba NP Tests for Detection and Classification of Carbapenemases
There is an urgent need for rapid, accurate detection and classification of carbapenemases. The current study evaluated the automated BD Phoenix CPO Detect and the manual bioMérieux Rapidec Carba NP tests for meeting these needs. Both tests were challenged with 294 isolates of Enterobacteriaceae spp., Pseudomonas aeruginosa , and Acinetobacter baumannii chosen to provide extreme diagnostic difficulty. Carbapenemases such as KPC, NMC-A, IMI, SME, NDM, SPM, IMP, VIM, and OXA-23, 40, 48, 58, 72, 181, and 232 were produced by 243 isolates and 51 carbapenemase-negative isolates included porin mutants and producers of extended-spectrum β-lactamases (ESBLs), AmpCs, K1, and broad-spectrum β-lactamases. Both tests exhibited high sensitivity of carbapenemase detection (>97%). Due to the highly challenging carbapenemase-negative isolates, specificities were lower than typical for evaluations involving mostly routine clinical isolates. BD Phoenix CPO Detect was 68.6% specific and Rapidec Carba NP was 60.8% to 78.4% specific, depending on how borderline results were interpreted. Only BD Phoenix CPO Detect classified carbapenemases. It correctly classified 85.0% of class A, 72.4% of class B, and 88.6% of class D carbapenemases. Importantly with respect to empirical therapy with new β-lactamase inhibitor combinations such as ceftazidime/avibactam, no class B carbapenemases were misclassified as class A carbapenemases. Both tests offer advantages. Used alone, without initial susceptibility tests, Rapidec Carba NP can provide positive results for some isolates after only 10 to 30 min incubation. BD Phoenix CPO Detect provides novel advantages such as automated carbapenemase detection, inclusion in susceptibility panels to eliminate delays and subjectivity in initiating carbapenemase tests, and classification of most carbapenemases.
- 1 June 2017
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 55 (6) , 1608-1611
The Immaculate Carbapenemase Study
Carbapenemase-producing organisms, or CPOs, are Gram-negative pathogens that produce a transmissible carbapenemase and are typically resistant to most (sometimes all) antibiotics. We now face a global CPO pandemic of high mortality. In this issue of the Journal of Clinical Microbiology , Karlowsky et al. (J Clin Microbiol 55:1638–1649, 2017, https://doi.org/10.1128/JCM.02316-16 ) report the results of an extensive global surveillance study that provide much-needed information that enhances our understanding of carbapenemase-producing Enterobacteriaceae (CPE) and which will be valuable for the development of improved strategies for CPE control and therapy of infections.
- 1 June 2017
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 55 (6) , 1608-1611
The Immaculate Carbapenemase Study
Carbapenemase-producing organisms, or CPOs, are Gram-negative pathogens that produce a transmissible carbapenemase and are typically resistant to most (sometimes all) antibiotics. We now face a global CPO pandemic of high mortality. In this issue of the Journal of Clinical Microbiology , Karlowsky et al. (J Clin Microbiol 55:1638–1649, 2017, https://doi.org/10.1128/JCM.02316-16 ) report the results of an extensive global surveillance study that provide much-needed information that enhances our understanding of carbapenemase-producing Enterobacteriaceae (CPE) and which will be valuable for the development of improved strategies for CPE control and therapy of infections.
- Open Access
- 1 January 2016
- Published by Elsevier in Current Therapeutic Research
- Vol. 83, 8-12
A Novel Topical Combination Ointment with Antimicrobial Activity against Methicillin-Resistant Staphylococcus aureus, Gram-Negative Superbugs, Yeasts, and Dermatophytic Fungi
- 1 January 2016
- Published by Elsevier in Current Therapeutic Research
- Vol. 83, 8-12
Open AccessA Novel Topical Combination Ointment with Antimicrobial Activity against Methicillin-Resistant Staphylococcus aureus, Gram-Negative Superbugs, Yeasts, and Dermatophytic Fungi
- Open Access
- 1 November 2015
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 53 (11) , 3705-3706
Indirect Tris-EDTA Disk Testing Using Imipenem and Meropenem for Detection of OXA-48 Carbapenemase Production
Enterobacteriaceae producing Class D OXA-48 and OXA-48-like carbapenemases are an increasing concern.…
- 1 November 2015
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 53 (11) , 3705-3706
Open AccessIndirect Tris-EDTA Disk Testing Using Imipenem and Meropenem for Detection of OXA-48 Carbapenemase Production
Enterobacteriaceae producing Class D OXA-48 and OXA-48-like carbapenemases are an increasing concern.…